You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Avapritinib is sold by Blueprint Medicines as Ayvakit for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation.
Promega will develop its microsatellite instability assay as a companion diagnostic for Incyte's anti-PD-1 drug candidate retifanlimab in endometrial cancer.
A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and were associated with lower response to aromatase inhibitors.
A pilot study enrolling up to 15 patients will validate CapeDx's utility to match patients to approved drugs and clinical trials based on whole-genome and tumor sequencing.
Amoy will develop its AmoyDx Pan Lung Cancer PCR Panel (9-in-1 Plus) as a companion diagnostic test for Haihe's MET kinase inhibitor Glumetinib.
Senaparib is currently being studied in a Phase II trial as a monotherapy for BRCA-mutated ovarian cancer patients who have received at least two prior lines of therapy.
AmoyDx aims to develop a companion diagnostic for Merck KGaA's non-small cell lung cancer treatment Tepmetko, which was recently approved in Japan.
Tumor microenvironment cell transcriptomes pointed to four stromal cell clusters, including immune interacting support cells predicted to impact immunotherapy response.
Avatamed will use the funds to expand into the Asia-Pacific market and set up a lab in Singapore to provide precision cancer drug screening services.
The drug is now approved in Hong Kong, China, and Taiwan as an extended adjuvant treatment for adult patients with early-stage, HER2-positive breast cancer.